HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tan, E.-K. Articles by Jankovic, J. Search for Related Content PubMed PubMed Citation Articles by Tan, E.-K. Articles by Jankovic, J.

Botulinum toxin A in patients with oromandibular dystonia

Long-term follow-up

From the Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX.

Address correspondence and reprint requests to Dr. Joseph Jankovic, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin Street, Smith 1801, Houston, TX 77030.

OBJECTIVE: To study the safety and efficacy of botulinum toxin A (BTX) in patients with oromandibular dystonia (OMD) and to compare the treatment results of the various subtypes of OMD.

BACKGROUND: OMD is one of the most challenging forms of dystonia to treat. Pharmacologic therapies are generally not effective, and there are no surgical alternatives.

METHODS: Of 202 patients diagnosed clinically to have OMD in a movement disorders clinic over a period of 10 years, 162 patients satisfied the study inclusion criteria. The masseters and submentalis complex were the only two muscle groups injected with BTX in this group of patients.

RESULTS: The mean age was 57.9 ± 15.3 years and the mean follow-up period was 4.4 ± 3.8 years. More than half the patients had jaw-closing (JC) dystonia. A total of 2,529 BTX treatments were administered into the masseter muscles, submentalis complex, or both during a total of 1,213 treatment visits. The mean doses of BTX (per side) were 54.2 ± 15.2 U for the masseters and 28.6 ± 16.7 U for the submentalis complex. The mean total duration of response was 16.4 ± 7.1 weeks. The mean global effect of BTX was 3.1 ± 1.0 (range, 0 to 4, where 4 equals the complete abolition of the dystonia), with the JC dystonia patients responding best. Fifty-one patients (31.5%) reported adverse effects with BTX in at least one visit. Complications such as dysphagia and dysarthria were reported in 135 (11.1%) of all treatment visits.

CONCLUSIONS: BTX is a safe and effective long-term treatment for OMD. JC dystonia responds better than jaw-opening or mixed dystonias, and the treatment of the latter types of OMD are more likely associated with dysphagia and dysarthria. Jaw-opening dystonia can be treated successfully by injecting the submentalis complex.

Key words: Oromandibular dystonia—Botulinum toxin—Long-term follow-up.

This article has been cited by other articles:

				I. Ugalde, S. P. Christiansen, and L. K. McLoon Botulinum Toxin Treatment of Extraocular Muscles in Rabbits Results in Increased Myofiber Remodeling Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4114 - 4120. [Abstract] [Full Text] [PDF]